Articles related to All Specialties

Orthopedic surgeon Dr. Ahmed Siddiqi wanted to find a better approach to postoperative monitoring – one that came closer to direct, continuous visibility of patient progress during recovery – while reducing the burden on patients and the management team. His new digital care solution enabled his team to provide long-term remote patient monitoring while directly communicating with all patients. The platform’s remote therapeutic monitoring (RTM) module helps the team meet the minimum engagement and data submission requirements to be eligible for RTM coverage.

Via the Internet of Medical Things (IoMT), medical devices share data with other systems and with physicians, and physicians remotely adjust settings as needed. But the very connectivity that makes the IoMT effective also makes it vulnerable to malicious parties.

AI is coming to medicine rapidly — likely more rapidly than many practitioners are prepared for. Peruse these six questions and follow the paths that most interest you to ensure you have positioned yourself to ride the coming wave.

In addition to recommending indexes over individual stocks and bonds, other recommendations include a 60/40 split between US and EU, Asia, and emerging markets and a solid “plan B” for physician in retirement, to avoid liquidating investments in a deep downturn.

TikTok is more than a potential security liability. It is also a valuable tool used by HCPs and their patients. A full ban would mean patients would lose access to useful health information. It also means loss of income and reach for some HCPs, and the ability to fight against misinformation.

The FDA has authorized the use of the mRNA bivalent COVID-19 vaccine (Moderna and Pfizer-BioNTech) for all doses administered to individuals 6 months of age and older. The monovalent vaccines are no longer authorized for use in the US. This simplifies the vaccination schedule and encourages future vaccination. For child vaccination, unvaccinated children may receive a 2-dose series of the Moderna bivalent vaccine (6 months through 5 years) or a 3-dose series of the Pfizer-BioNTech bivalent vaccine (6 months through 4 years). Children who are 5 years old may receive 2 doses of Moderna bivalent vaccine or a single dose of Pfizer-BioNTech bivalent vaccine. For immunocompromised children 6 months through 4 years, eligibility depends on the vaccine previously received. For individuals 5 years of age and older with certain kinds of immunocompromise, a single additional dose of bivalent vaccine may be administered at least 2 months following the initial dose of a bivalent vaccine. Additional doses may be administered at the discretion of the health care provider, taking into consideration the individual’s clinical circumstances.